Zilretta Benefits 'Real-World' Patients With Knee OA, Says Study

Average time to second injection was more than 16 weeks
Average time to second injection was more than 16 weeks

Flexion Therapeutics announced interim data from a Phase 3b, open-label study that evaluated the safety and tolerability of repeat administration of Zilretta (triamcinolone acetonide extended-release injectable suspension) in patients with osteoarthritis (OA) of the knee.

The new data, presented at the Osteoarthritis Research Society International (OARSI) 2018 World Congress, comes from a real-world study involving patients with knee OA, including those who were previously treated with intra-articular corticosteroids (51.9%). 

Study patients received an initial injection of Zilretta with follow-up at Weeks 12, 16, 20 or 24 to determine eligibility for a second injection. Those who received the second injection were followed for a total of 52 weeks and underwent physical exams, knee assessments, and X-rays. The results showed that 74% of patients received a second injection of Zilretta between Weeks 16 and 24 (average time to second administration: 16.6 weeks). 

Patients who received a repeat Zilretta injection experienced a 64% improvement in Western Ontario and McMaster Universities Arthritis Index (WOMAC)-A (pain), a 66% improvement in WOMAC-B (stiffness), a 64% improvement on WOMAC-C (function), and improvement represented by a doubling of the KOOS Quality of Life subscale score by Week 4. These effects were sustained in a substantial proportion of patients through Week 12. Full findings are anticipated in the third quarter of 2018. 

Related Articles

Zilretta was approved in October 2017 as an intra-articular injection for patients with OA-related knee pain. It utilizes a proprietary microsphere technology combining triamcinolone acetonide with a poly lactic-co-glycolic acid (PLGA) matrix to provide extended pain relief over 12 weeks. 

For more information call (844) 353-9466 or visit Zilretta.com.